Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2017
Pharma News, 2017
JPM: Wondering how Teva overestimated 2017 sales by $1B-plus? Let CEO Vigodman explain
SAN FRANCISCO, Jan 10, 2017 — Last week, Teva had to slash more than $1 billion off the 2017 sales guidance it announced last July.
Antioxidant found in breast milk prevents liver disease, study finds
Antioxidants are believed to prevent some chronic illnesses - such as cardiovascular disease and cancer - due to their ability to protect against cell damage.
Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds
DUBLIN and CAMBRIDGE, Mass.
A Drug Meant for Alzheimer’s Treatment Regrows Human Teeth
Goodbye, cavities.
NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer
SAN DIEGO, Jan.
Viriom Announces Collaboration with NIH on Zika and Other Major Viral Diseases
SAN DIEGO, CA, USA I January 6, 2017 I Viriom Inc.
Investigation Into New Molecules That Could Potentially Treat Alzheimer’s
Scientists investigated two molecules that have a high pharmaceutical potential and low toxicity.
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
HALLE (SAALE), Germany I January 9, 2017 I Probiodrug AG ("Probiodrug", Euronext.
Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities
INDIANAPOLIS, Jan.
Ipsen to buy cancer drugs from Merrimack
French drugmaker Ipsen has entered into a definitive agreement to buy the global oncology assets from the USA's Merrimack Pharmaceuticals, in a deal that could be worth around $1 billion.
Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal
Japan's Takeda Pharmaceutical Co Ltd (4502.
67
68
69
70
71
